What are the indications for use of tolvaptan in the treatment of autosomal dominant polycystic kidney disease (ADPKD)?

Updated: Mar 24, 2020
  • Author: Roser Torra, MD, PhD; Chief Editor: Vecihi Batuman, MD, FASN  more...
  • Print

Tolvaptan (Jynarque), a selective vasopressin V2-receptor antagonist, was approved in the U.S. in April 2018 to slow kidney function decline in adults at risk of rapidly progressing ADPKD. Approval was based on several phase 3 clinical trials. [38, 37, 39]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!